Skip to content

Study · Randomized controlled trial · n = 27 · 2017

3 results

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.

von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, Hansen TW, Rossing P

Diabetes, obesity & metabolism2 Mar 2017Cited by 58 (Europe PMC)

PMID28105731 (opens in a new tab)DOI10.1111/dom.12884 (opens in a new tab)PepBankPUB-28105731
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, liraglutide lowered TNF-alpha levels compared with placebo.

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide lowered an inflammation marker (TNF-alpha) compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTNF-alpha level
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    TNF-alpha reduction
    12%
    liraglutide vs placebo

    Source sentences

    Summary
    TNF-α level was 12% (95% confidence interval [CI] 3; 20) lower after liraglutide treatment compared with placebo (P = .012)
    2 context sentences
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial we enrolled people with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio [UACR] >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Participants received liraglutide (1.8 mg/d) and matched placebo for 12 weeks, in random order.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, liraglutide lowered MR-proADM levels compared with placebo.

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide lowered a heart risk marker (MR-proADM) compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMR-proADM level
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    MR-proADM reduction
    4%
    liraglutide vs placebo

    Source sentences

    Summary
    MR-proADM level was 4% (95% CI 0; 8) lower after liraglutide treatment compared with placebo (P = .038)
    2 context sentences
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial we enrolled people with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio [UACR] >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Participants received liraglutide (1.8 mg/d) and matched placebo for 12 weeks, in random order.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, liraglutide lowered MR-proANP levels compared with placebo.

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide lowered a heart strain marker (MR-proANP) compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMR-proANP level
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    MR-proANP reduction
    13%
    liraglutide vs placebo

    Source sentences

    Summary
    MR-proANP level was 13% (95% CI 4; 21) lower after liraglutide treatment compared with placebo (P = .006).
    2 context sentences
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial we enrolled people with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio [UACR] >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Participants received liraglutide (1.8 mg/d) and matched placebo for 12 weeks, in random order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.